EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

FCRL1 and BAFF mRNA Expression as Novel Diagnostic and Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma: Expression Signatures Predict R-CHOP Therapy Response and Survival

Hiba S Al-Amodi iD, Hanan M Bedair iD, Suzy Gohar iD, Dalia Abdel-Wahab Mohamed, Eman M Abd El Gayed, Mahmoud Nazih, Sahar Badr Hassan, Eman S Sawan, Esraa Elsayed Elmahdy, Asmaa Mosbeh, Alaa Efat iD, Shimaa Abdelsattar iD

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26031269 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hiba S Al-Amodi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Biochemistry Department, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia. Hauptthemen laut MEDLINE: Lymphoma, Large B-Cell, Diffuse, Antineoplastic Combined Chemotherapy Protocols, B-Cell Activating Factor, Biomarkers, Tumor. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigated the diagnostic, prognostic, and therapeutic significance of Fc receptor-like 1 (FCRL1) and B-cell activating factor (BAFF) mRNA expression in Egyptian patients with diffuse large B-cell lymphoma (DLBCL) undergoing the standard R-CHOP regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) using quantitative real-time PCR (RT-qPCR). The results demonstrated that FCRL1 and BAFF mRNA expression were significantly elevated in DLBCL patients compared to healthy controls. A strong positive correlation existed between BAFF and FCRL1 expression levels. Diagnostic performance assessed through combined ROC curve analysis revealed that BAFF, FCRL1, and lactate dehydrogenase (LDH) achieved perfect diagnostic accuracy (AUC = 1.0), demonstrating 100% sensitivity, specificity, and predictive values. Further prognostic analysis using COX regression identified elevated FCRL1 expression as the most significant predictor of poor clinical outcomes. Kaplan–Meier survival analysis reinforced this finding, with high FCRL1 expression showing significant associations with reduced overall survival (OS, p = 0.031) and progression-free survival (PFS, p = 0.038). The study underscores the potential utility of BAFF and FCRL1 mRNA as diagnostic markers for DLBCL, with FCRL1 emerging as a promising prognostic marker and potential therapeutic target enabling more tailored treatment approaches for DLBCL, the most common type of B-cell non-Hodgkin lymphoma, and patients receiving R-CHOP therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Lymphoma, Large B-Cell, DiffuseAntineoplastic Combined Chemotherapy ProtocolsB-Cell Activating FactorBiomarkers, TumorReceptors, FcHumansDoxorubicinCyclophosphamideVincristineMaleRituximabFemalePrednisoneMiddle AgedPrognosisRNA, MessengerAdultAgedGene Expression Regulation, NeoplasticYoung AdultKaplan-Meier Estimate

Stichwörter der Autor:innen

B-cell non-Hodgkin lymphomaBAFFDLBCLFCRL1R-CHOP therapymRNA expression

Substanzen

DoxorubicinCyclophosphamideVincristineRituximabPrednisoneB-Cell Activating FactorR-CHOP protocolBiomarkers, TumorRNA, MessengerReceptors, Fc

Autor:innen und Institutionen

  • Biochemistry Department, Faculty of Medicine, Umm Al-Qura University, Makkah 21955, Saudi Arabia.
  • Clinical Pathology Department, National Liver Institute, Menoufia University, Menofia 32511, Egypt.
  • Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Menoufia University, Menofia 32511, Egypt.
  • Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Ain Shams University, Cairo 11381, Egypt.
  • Medical Biochemistry and Molecular Biology Department, Faculty of Medicine, Menoufia University, Menofia 32511, Egypt.
  • Al Ryada University for Science and Technology (RST), ElMehwar ElMarkazy-2, Cairo-Alex Desert RD K92, Sadat City 16504, Egypt.

ORCID-Profile: Hiba S Al-Amodi, Hanan M Bedair, Suzy Gohar, Alaa Efat, Shimaa Abdelsattar

Zitieren

APA

Al-Amodi, H. S., Bedair, H. M., Gohar, S., Mohamed, D. A., Abd El Gayed, E. M., Nazih, M., Hassan, S. B., Sawan, E. S., Elmahdy, E. E., Mosbeh, A., Efat, A., & Abdelsattar, S. (2025). FCRL1 and BAFF mRNA Expression as Novel Diagnostic and Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma: Expression Signatures Predict R-CHOP Therapy Response and Survival. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26031269

Vancouver

Al-Amodi HS, Bedair HM, Gohar S, Mohamed DA, Abd El Gayed EM, Nazih M, et al. FCRL1 and BAFF mRNA Expression as Novel Diagnostic and Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma: Expression Signatures Predict R-CHOP Therapy Response and Survival. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26031269

BibTeX
@article{AlAmodi2025,
  author = {Al-Amodi, Hiba S and Bedair, Hanan M and Gohar, Suzy and Mohamed, Dalia Abdel-Wahab and Abd El Gayed, Eman M and Nazih, Mahmoud and Hassan, Sahar Badr and Sawan, Eman S and Elmahdy, Esraa Elsayed and Mosbeh, Asmaa and Efat, Alaa and Abdelsattar, Shimaa},
  title = {FCRL1 and BAFF mRNA Expression as Novel Diagnostic and Prognostic Biomarkers in Diffuse Large B-Cell Lymphoma: Expression Signatures Predict R-CHOP Therapy Response and Survival},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26031269}
}
Kostenlos starten →